Latest News of INSM
The Chainsmokers want to bring a different kind of value add to B2B companies
By TechCrunch |
3 weeks ago
The Chainsmokers, through their VC fund Mantis VC, aim to bring unique value to B2B startups beyond traditional VCs by leveraging their network and providing a different level of support and perspecti...
Do You Believe in the Growth Potential of Insmed (INSM)?
By Yahoo! Finance |
3 weeks ago
Baron Funds' "Baron Health Care Fund" Q3 2024 investor letter reveals a 5.81% gain compared to benchmarks. Highlighting Insmed Incorporated (NASDAQ:INSM), the biopharmaceutical company saw a one-month...
Decoding Insmed Inc (INSM): A Strategic SWOT Insight
By Yahoo! Finance |
3 weeks ago
Insmed Inc faces potential financial challenges from market volatility and competition. Despite a strong balance sheet and robust product pipeline, operational losses persist due to high research and ...
-
How to play biotech stocks: Insmed and Wave Life Sciences
By Yahoo! Finance | 3 weeks agoEmerald Growth Fund's Stacey Sears suggests investing in small-cap biotech companies for growth opportunities in the healthcare sector. DNA and RNA editing advancements have led to breakthroughs in or...
-
How The Chainsmokers built a fund that doesn't rely on their celebrity status
By TechCrunch | 3 weeks agoThe Chainsmokers, Drew Taggart and Alex Pall, stand out by launching Mantis Venture Capital to invest in various industries beyond their celebrity status. They support B2B startups like security and a...
-
TechCrunch Disrupt 2024: GM CEO Mary Barra, Tony Fadell and The Chainsmokers
By TechCrunch | 3 weeks agoAccessing quality data for training AI systems is a challenge. Advex AI aims to tackle this issue, as highlighted in the Startup Battlefield. Vinod Khosla discusses the potential of AI and its risks, ...
-
Is Insmed Inc. (INSM) the Best Performing Stock in 2024?
By Yahoo! Finance | 1 month agoInsmed Inc. (NASDAQ:INSM) is a leading biopharmaceutical company focusing on rare lung diseases. Their innovative therapies show promise, positioning them as a top performer in 2024....
-
Insmed Inc. (INSM): A Top Mid-Cap Biopharma Stock with Compelling Growth Potential
By Yahoo! Finance | 2 months agoInsmed Inc. (NASDAQ:INSM) is a top mid-cap growth stock to buy, excelling in biopharmaceutical innovation with positive revenue growth and promising drug development....
-
Insmed Incorporated (INSM) Surged Following Positive Data For its Drug
By Yahoo! Finance | 2 months agoThe Columbia Acorn Fund's Q2 2024 investor letter discussed the fund's -6.01% return compared to the benchmark's -4.22%, attributing underperformance to disappointing earnings....
-
Insmed Incorporated (INSM): Hedge Funds Are Recommending This Biotech Stock Now
By Yahoo! Finance | 2 months agoInsmed Incorporated (NASDAQ:INSM) is a promising biopharmaceutical company in the biotech industry with a strong market presence. Its recent developments and growth potential make it a top choice for ...
-
Insmed (INSM) Rose Due to Positive Trial Results
By Yahoo! Finance | 2 months agoCarillon Tower Advisers released its Q2 2024 investor letter highlighting the Carillon Eagle Small Cap Growth Fund's performance. Small-cap stocks ended the quarter negatively....
-
Insmed Incorporated (NASDAQ:INSM) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
By Yahoo! Finance | 3 months agoInsmed Incorporated's latest second-quarter results showed a 3.0% share price increase to US$73.98, with revenues exceeding expectations at US$90m. Analysts expect an 8.9% revenue increase in 2024, bu...
-
What Makes Insmed Incorporated (INSM) a Prospective Investment?
By Yahoo! Finance | 4 months agoArtisan Partners' "Artisan Mid Cap Fund" Q2 2024 investor letter reported negative returns, underperforming the index. Notable stock pick Insmed Incorporated (NASDAQ:INSM) showed promising growth pote...
-
Insmed Incorporated (INSM) Stock Price, News, Quote & History
By Yahoo! Finance | 4 months agoInsmed Incorporated is a biopharmaceutical company that focuses on developing and marketing therapies for patients with rare and serious diseases worldwide. Their product portfolio includes ARIKAYCE f...
-
More endpoints met in Insmed's Phase III brensocatib trial
By Yahoo! Finance | 4 months agoInsmed's Phase III ASPEN trial data reveals brensocatib's effectiveness in reducing lung function decline in bronchiectasis patients. Positive results support potential approval as a chronic treatment...